GS Paper III · Science & Technology · Biotechnology
🛡 CAR T-Cell Therapy — Cancer Immunotherapy
Chimeric Antigen Receptor · Personalised Cancer Treatment · T Cell Engineering · NexCAR19 (India's ₹30 Lakh Therapy) · CD19 & BCMA Targets · CRS Side Effects · 4 Generations · Kymriah & Yescarta (FDA) · ImmunoACT + Tata Memorial + IIT Bombay
🛡
What is CAR T-Cell Therapy?
Chimeric Antigen Receptor · Personalised Immunotherapy · Living Drug
📖 Definition
CAR T-Cell Therapy is a type of cancer immunotherapy in which a patient's own T cells (immune cells) are extracted, genetically engineered in a lab to produce special receptors called Chimeric Antigen Receptors (CARs) on their surface, expanded to hundreds of millions, and then infused back into the patient. These engineered CAR T cells can recognise, bind to, and kill cancer cells that display a specific target antigen. Unlike chemotherapy (which kills all dividing cells) or general immunotherapy (which boosts the entire immune system), CAR T-cell therapy is a personalised, targeted "living drug" — made from the patient's own cells and designed to hunt a specific cancer.
🏏 Simple Analogy — The "GPS-Guided Missile" Upgrade
Your immune system's T cells are like soldiers — they patrol the body looking for threats. But cancer cells are clever — they disguise themselves so the soldiers walk right past. CAR T-cell therapy is like taking a soldier to a lab, fitting them with GPS goggles programmed to the cancer's exact location, cloning millions of these upgraded soldiers, and sending them back into battle. The CAR receptor is the "GPS" — it locks onto a specific protein on the cancer cell's surface. Once locked, the soldier (T cell) activates and destroys the cancer cell. And the best part? These upgraded soldiers stay in the body for years, patrolling for cancer's return.
🔑
What is "CAR"?
C = Chimeric (engineered combination)
A = Antigen (target molecule on cancer cell)
R = Receptor (lock-and-key protein on T cell)
The CAR is an artificial receptor — it doesn't exist naturally. Scientists design it by combining an antibody fragment (that recognises the cancer antigen) with signalling domains (that activate the T cell). When the CAR locks onto the cancer antigen, it triggers the T cell to kill.
A = Antigen (target molecule on cancer cell)
R = Receptor (lock-and-key protein on T cell)
The CAR is an artificial receptor — it doesn't exist naturally. Scientists design it by combining an antibody fragment (that recognises the cancer antigen) with signalling domains (that activate the T cell). When the CAR locks onto the cancer antigen, it triggers the T cell to kill.
🆚
How is CAR-T Different from Other Treatments?
Chemotherapy: Kills all fast-dividing cells (cancer AND healthy) → severe side effects.
Radiation: Targets a specific area but damages nearby tissue.
General immunotherapy (checkpoint inhibitors): Boosts overall immune system → may not be cancer-specific.
CAR-T: Engineered to target ONLY the specific cancer → personalised, precise, and can persist for years as a "living drug."
Radiation: Targets a specific area but damages nearby tissue.
General immunotherapy (checkpoint inhibitors): Boosts overall immune system → may not be cancer-specific.
CAR-T: Engineered to target ONLY the specific cancer → personalised, precise, and can persist for years as a "living drug."
⚙
How CAR T-Cell Therapy Works — 5 Steps
Collection → Engineering → Expansion → Infusion → Cancer Killing
CAR T-Cell Therapy — 5 Steps: ① Remove blood → get T cells ② Insert CAR gene in lab ③ Grow millions of CAR T cells ④ Infuse back into patient ⑤ CAR T cells bind to and kill cancer cells
📊 Legacy IAS — CAR T-Cell Therapy: 5-Step Process Explained
💡 Why "Living Drug"?
Unlike a pill or injection that gets metabolised and leaves the body, CAR T cells are living cells that multiply, adapt, and persist in the patient's body for months to years. They continue patrolling for cancer cells long after infusion — providing durable anti-cancer surveillance. Some patients have shown no cancer relapse for 10+ years after a single CAR T infusion. However, some cancers can escape by stopping expression of the target antigen — the CAR T cells can no longer "see" them.
🇮🇳
India's NexCAR19 — A Game Changer
ImmunoACT · Tata Memorial · IIT Bombay · CDSCO Approved 2023 · ₹30 Lakh
🇮🇳 NexCAR19 — INDIA'S FIRST INDIGENOUS CAR T-CELL THERAPY Critical Current Affairs
In October 2023, India's drug regulator CDSCO approved NexCAR19 — India's first domestically developed CAR T-cell therapy.
Developed by: ImmunoACT, a company incubated at IIT Bombay, in collaboration with Tata Memorial Hospital (Mumbai).
Target: CD19 antigen on B-cell cancers (leukaemia and lymphoma) in patients above 15 years.
Cost: ~₹30–40 lakhs — vs ₹3–4 crore for Kymriah/Yescarta in the USA. ~10× cheaper!
By July 2025: Administered in 350+ patients across 70+ hospitals in India.
Quartemi: ImmunoACT's second CAR-T therapy for non-Hodgkin B-cell chronic lymphocytic leukaemia — also launched.
Why this matters for UPSC: NexCAR19 demonstrates India's growing capability in advanced cell and gene therapy. It's a public-private-academic collaboration (hospital + IIT + startup) that made cutting-edge cancer treatment affordable. It aligns with India's goal of becoming a global biopharma leader.
Developed by: ImmunoACT, a company incubated at IIT Bombay, in collaboration with Tata Memorial Hospital (Mumbai).
Target: CD19 antigen on B-cell cancers (leukaemia and lymphoma) in patients above 15 years.
Cost: ~₹30–40 lakhs — vs ₹3–4 crore for Kymriah/Yescarta in the USA. ~10× cheaper!
By July 2025: Administered in 350+ patients across 70+ hospitals in India.
Quartemi: ImmunoACT's second CAR-T therapy for non-Hodgkin B-cell chronic lymphocytic leukaemia — also launched.
Why this matters for UPSC: NexCAR19 demonstrates India's growing capability in advanced cell and gene therapy. It's a public-private-academic collaboration (hospital + IIT + startup) that made cutting-edge cancer treatment affordable. It aligns with India's goal of becoming a global biopharma leader.
💰
Cost Comparison — India vs World
Kymriah (USA): ~$475,000 (~₹4 crore) per treatment
Yescarta (USA): ~$373,000 (~₹3.1 crore) per treatment
NexCAR19 (India): ~₹30–40 lakhs → hospitals aiming for ₹10–20 lakhs
India's therapy is 10–20× cheaper — making CAR-T accessible to middle-income patients for the first time. Target: bring cost to ₹10–20 lakhs.
Yescarta (USA): ~$373,000 (~₹3.1 crore) per treatment
NexCAR19 (India): ~₹30–40 lakhs → hospitals aiming for ₹10–20 lakhs
India's therapy is 10–20× cheaper — making CAR-T accessible to middle-income patients for the first time. Target: bring cost to ₹10–20 lakhs.
🌍
Global Approvals Timeline
2017: Kymriah (Novartis) — FDA approved for B-ALL
2017: Yescarta (Gilead) — FDA approved for DLBCL
2021: Abecma — FDA approved for multiple myeloma (BCMA target)
2023: NexCAR19 (India) — CDSCO approved for B-cell cancers
6 FDA-approved CAR-T products as of 2025.
2017: Yescarta (Gilead) — FDA approved for DLBCL
2021: Abecma — FDA approved for multiple myeloma (BCMA target)
2023: NexCAR19 (India) — CDSCO approved for B-cell cancers
6 FDA-approved CAR-T products as of 2025.
📋
Types of CAR T Cells & Generations
CD19 · BCMA · 4 Generations of CAR Design
| CAR Target | Cancer Type | Key Details |
|---|---|---|
| CD19 | B-cell leukaemias & lymphomas | Most established target. High remission rates in B-ALL. Used in Kymriah, Yescarta, NexCAR19. CD19 is on all B cells (including normal ones — causes B-cell depletion side effect). |
| BCMA | Multiple myeloma | B-cell maturation antigen on myeloma cells. Robust response rates. Used in Abecma, Carvykti. |
| CD20, CD22, CD30 | Various blood cancers | Being evaluated in clinical trials. May help when CD19-targeted therapy fails (antigen escape). |
| Solid tumour targets (MUC1, etc.) | Breast, lung, pancreatic cancers | Early-phase trials. Major challenge: solid tumours have hostile microenvironment that suppresses T cells. Limited efficacy so far. |
| Generation | Design | Key Feature |
|---|---|---|
| 1st Gen | CD3-zeta only | Suboptimal T cell activation. Low persistence. Limited clinical success. |
| 2nd Gen | CD3-zeta + 1 costimulatory domain (CD28 or 4-1BB) | Current standard. Improved activation + persistence. All approved therapies are 2nd gen. |
| 3rd Gen | CD3-zeta + 2 costimulatory domains | Greater activity but increased toxicity risk. In clinical trials. |
| 4th Gen (TRUCKs) | 2nd/3rd gen + cytokine expression | CAR T cells also release cytokines to recruit other immune cells. Enhanced efficacy. "Armoured" CAR T cells. |
🧠 Memory Aid — "Generations = Upgrades"
Think of CAR generations like smartphone upgrades: 1st gen = basic phone (calls only). 2nd gen = smartphone (calls + apps — the one everyone uses). 3rd gen = gaming phone (more power, but battery drains faster = more toxicity). 4th gen = AI phone (does everything + calls for backup). The 2nd generation is the current sweet spot — all approved therapies use it.
⚠
Side Effects, Challenges & Limitations
CRS · Neurotoxicity · Antigen Escape · Cost · Solid Tumour Barrier
🌡
Cytokine Release Syndrome (CRS)
The most common serious side effect. When CAR T cells activate massively, they release a storm of inflammatory cytokines. Symptoms: high fever, low BP, difficulty breathing, organ toxicity. Can be life-threatening. Managed with tocilizumab (IL-6 blocker) and steroids. Occurs in 50–90% of patients (mild to severe).
🧠
Neurotoxicity (ICANS)
Immune effector cell-associated neurotoxicity. Symptoms: confusion, delirium, seizures, cerebral oedema. Related to cytokine elevation. Usually reversible with supportive care. Occurs in 20–60% of patients. Onset: typically 4–10 days after infusion.
🏃
Antigen Escape & Relapse
Some cancers stop expressing the target antigen (e.g., CD19) to evade CAR T cells — like a criminal changing disguises. The CAR T cells can no longer "see" the cancer. Solution: CAR T cells targeting multiple antigens simultaneously (dual-targeting CARs).
🧊
Solid Tumour Challenge
CAR-T works well for blood cancers (cells floating in blood/lymph). Solid tumours are much harder: the tumour microenvironment suppresses T cells, blood supply is irregular, and target antigens are often also on normal tissue. This is the biggest unsolved challenge in CAR-T research.
📜
Previous Year Questions & Practice MCQs
UPSC Prelims · GS Paper III · CAR-T & Immunotherapy
📜 UPSC CSE Prelims2019
Q. What is Cas9 protein that is often mentioned in the news?
- (a) A molecular scissors used in targeted gene editing ✅
- (b) A biosensor used in laboratory
- (c) A gene that makes plants pest-resistant
- (d) A herbicidal substance
Link to CAR-T: While Cas9 (CRISPR) is gene editing, CAR-T therapy uses viral vectors (not CRISPR) to insert the CAR gene into T cells. However, next-generation CAR-T research IS exploring CRISPR-based CAR insertion for more precise engineering. UPSC often tests whether students can distinguish between CRISPR (gene editing), RNAi (gene silencing), and CAR-T (immune cell engineering). All three involve genetic modification but in fundamentally different ways.
📜 UPSC CSE Prelims — Related2021
Q. Consider the following statements:
1. Monoclonal antibodies are made by immune cells that are all clones of a unique parent cell.
2. Monoclonal antibodies can be used in cancer treatment.
Which of the above statements is/are correct?
1. Monoclonal antibodies are made by immune cells that are all clones of a unique parent cell.
2. Monoclonal antibodies can be used in cancer treatment.
Which of the above statements is/are correct?
- (a) 1 only
- (b) 2 only
- (c) Both 1 and 2 ✅
- (d) Neither 1 nor 2
Link to CAR-T: CAR-T therapy and monoclonal antibodies are both immunotherapy approaches against cancer, but they work differently. Monoclonal antibodies are proteins that bind cancer cells (passive immunity). CAR-T cells are living, engineered immune cells that actively hunt and kill cancer (active, personalised immunity). UPSC may test this distinction. Both use the principle of antigen-antibody/receptor specificity — but CAR-T is cellular therapy while mAbs are protein therapy.
🎯 Practice MCQs — Test Your Understanding (Click to Answer)
Q1. NexCAR19, India's first CAR T-cell therapy approved by CDSCO in 2023, was developed by:
- (a) Bharat Biotech in collaboration with ICMR and AIIMS Delhi
- (b) Serum Institute of India in collaboration with CSIR-IGIB
- (c) ImmunoACT in collaboration with Tata Memorial Hospital and IIT Bombay
- (d) Biocon in collaboration with CDFD Hyderabad and CCMB
✅ (c). NexCAR19 was developed by ImmunoACT, a company incubated at IIT Bombay, in collaboration with Tata Memorial Hospital (one of India's premier cancer centres). It targets CD19 on B-cell cancers. Cost: ~₹30–40 lakhs (vs ₹3–4 crore globally). By July 2025, administered in 350+ patients across 70+ hospitals. This is a classic UPSC fact-check question — remember the specific institutions involved.
Q2. What makes CAR T-cell therapy different from conventional chemotherapy?
- (a) Chemotherapy uses the patient's own cells; CAR-T uses donor cells
- (b) CAR-T kills all dividing cells; chemotherapy targets only cancer cells
- (c) CAR-T is cheaper and more widely available than chemotherapy
- (d) CAR-T engineers the patient's own immune cells to specifically target cancer antigens, while chemotherapy kills all fast-dividing cells non-specifically
✅ (d). CAR-T therapy is personalised and targeted — it engineers the patient's OWN T cells with receptors specific to cancer antigens. Chemotherapy is non-specific — it kills all rapidly dividing cells (cancer AND healthy cells like hair, gut lining). Option (a) has it reversed. Option (b) has it reversed. Option (c) is wrong — CAR-T is currently MORE expensive (₹30+ lakhs vs chemotherapy at ₹5–10 lakhs) and LESS available.
Q3. Cytokine Release Syndrome (CRS), a major side effect of CAR T-cell therapy, occurs because:
- (a) The CAR gene mutates inside the patient's body and produces toxic proteins
- (b) Massive activation of CAR T cells releases a storm of inflammatory cytokines, causing fever, low BP, and organ toxicity
- (c) The viral vector used to insert the CAR gene causes a secondary viral infection
- (d) Cancer cells release toxins when they die, poisoning the patient's liver and kidneys
✅ (b). CRS is caused by the massive, simultaneous activation of CAR T cells when they encounter cancer cells. The activated T cells release large quantities of inflammatory cytokines (IL-6, IFN-gamma, TNF-alpha) — creating a "cytokine storm." Symptoms include high fever, dangerously low blood pressure, difficulty breathing, and organ dysfunction. Managed with tocilizumab (an IL-6 receptor blocker). CRS occurs in 50–90% of patients but is usually manageable.
Q4. Consider the following statements about CAR T-cell therapy:
1. It has been highly effective against solid tumours like breast and lung cancer.
2. All approved CAR T-cell therapies currently use 2nd generation CAR design.
3. CAR T cells can persist in the body for years, providing ongoing cancer surveillance.
Which of the above statements is/are correct?
1. It has been highly effective against solid tumours like breast and lung cancer.
2. All approved CAR T-cell therapies currently use 2nd generation CAR design.
3. CAR T cells can persist in the body for years, providing ongoing cancer surveillance.
Which of the above statements is/are correct?
- (a) 1 and 2 only
- (b) 1 and 3 only
- (c) 2 and 3 only
- (d) 1, 2 and 3
✅ (c) 2 and 3 only. Statement 1 is WRONG — CAR-T has been highly effective against blood cancers (leukaemias, lymphomas, myeloma). It has shown limited efficacy against solid tumours so far — the hostile tumour microenvironment suppresses T cell function. This is the biggest unsolved challenge. Statement 2 is correct — all FDA/CDSCO approved CAR-T therapies use 2nd generation CARs (CD3-zeta + one costimulatory domain). Statement 3 is correct — CAR T cells can persist for months to years, acting as a "living drug."
⚡ Quick Revision — CAR T-Cell Therapy Summary
| Topic | Key Facts |
|---|---|
| Basics | CAR = Chimeric Antigen Receptor. Personalised cancer immunotherapy. Patient's T cells extracted → engineered with CAR gene → expanded → infused back. "Living drug" — persists for years. Targets specific cancer antigens. |
| Process | 5 steps: T cell collection (apheresis) → Genetic engineering (viral vector inserts CAR gene) → Expansion (2–3 weeks, hundreds of millions) → Chemo pretreatment → Infusion → CAR T cells kill cancer via perforin + granzymes. |
| India — NexCAR19 | First Indian CAR-T. CDSCO approved Oct 2023. By ImmunoACT + Tata Memorial + IIT Bombay. CD19 target. ~₹30-40 lakhs (10× cheaper than USA). 350+ patients by Jul 2025. Quartemi (2nd product) also launched. |
| Global Approvals | Kymriah (2017, Novartis, B-ALL). Yescarta (2017, Gilead, DLBCL). Abecma (2021, myeloma). 6 FDA-approved products total. All are 2nd generation CARs. |
| 4 Generations | 1st: CD3-zeta only (weak). 2nd: + 1 costimulatory domain (CURRENT STANDARD). 3rd: + 2 costimulatory (more power, more toxicity). 4th (TRUCKs): + cytokine secretion (armoured). |
| Side Effects | CRS (cytokine storm — fever, low BP, organ toxicity; managed with tocilizumab). Neurotoxicity/ICANS (confusion, seizures; usually reversible). On-target off-tumour (kills normal B cells too). B-cell aplasia. |
| Challenges | Antigen escape (cancer stops showing target). Solid tumours resistant (hostile microenvironment). High cost. Complex manufacturing. Relapses in some patients. |
🚨 5 UPSC Traps — CAR T-Cell Therapy:
Trap 1 — "CAR-T works well against all cancers" → WRONG! CAR-T has been highly effective against blood cancers (leukaemia, lymphoma, myeloma). It has shown limited success against solid tumours (breast, lung, pancreatic). The solid tumour microenvironment suppresses T cell function.
Trap 2 — "CAR-T uses CRISPR to edit T cells" → MOSTLY WRONG! Current approved CAR-T therapies use viral vectors (lentiviruses/retroviruses) to insert the CAR gene — not CRISPR. CRISPR-based CAR insertion is being explored in research but is NOT yet in approved therapies. Don't confuse gene editing (CRISPR) with gene insertion (viral vectors).
Trap 3 — "NexCAR19 was developed by Serum Institute" → WRONG! NexCAR19 was developed by ImmunoACT + Tata Memorial Hospital + IIT Bombay. Serum Institute is involved in BIRSA 101 (CRISPR sickle cell therapy), not CAR-T. Don't mix up India's biotech landmarks.
Trap 4 — "CRS means the therapy failed" → WRONG! Cytokine Release Syndrome actually indicates that CAR T cells are working — they're activating massively against cancer. CRS is a sign of efficacy, not failure. It's a manageable side effect, treated with tocilizumab. Severity ranges from mild fever to life-threatening organ toxicity.
Trap 5 — "CAR-T and monoclonal antibodies are the same" → WRONG! Both target cancer antigens, but: Monoclonal antibodies = proteins (passive, need repeated doses). CAR T cells = living cells (active, self-multiplying, persist for years). CAR-T is cellular therapy; mAbs are protein therapy. CAR-T is personalised (from patient's own cells); most mAbs are off-the-shelf.
Trap 1 — "CAR-T works well against all cancers" → WRONG! CAR-T has been highly effective against blood cancers (leukaemia, lymphoma, myeloma). It has shown limited success against solid tumours (breast, lung, pancreatic). The solid tumour microenvironment suppresses T cell function.
Trap 2 — "CAR-T uses CRISPR to edit T cells" → MOSTLY WRONG! Current approved CAR-T therapies use viral vectors (lentiviruses/retroviruses) to insert the CAR gene — not CRISPR. CRISPR-based CAR insertion is being explored in research but is NOT yet in approved therapies. Don't confuse gene editing (CRISPR) with gene insertion (viral vectors).
Trap 3 — "NexCAR19 was developed by Serum Institute" → WRONG! NexCAR19 was developed by ImmunoACT + Tata Memorial Hospital + IIT Bombay. Serum Institute is involved in BIRSA 101 (CRISPR sickle cell therapy), not CAR-T. Don't mix up India's biotech landmarks.
Trap 4 — "CRS means the therapy failed" → WRONG! Cytokine Release Syndrome actually indicates that CAR T cells are working — they're activating massively against cancer. CRS is a sign of efficacy, not failure. It's a manageable side effect, treated with tocilizumab. Severity ranges from mild fever to life-threatening organ toxicity.
Trap 5 — "CAR-T and monoclonal antibodies are the same" → WRONG! Both target cancer antigens, but: Monoclonal antibodies = proteins (passive, need repeated doses). CAR T cells = living cells (active, self-multiplying, persist for years). CAR-T is cellular therapy; mAbs are protein therapy. CAR-T is personalised (from patient's own cells); most mAbs are off-the-shelf.
